Accepting New Patients
Dorothy Pan, MD
Associate Professor of Medicine
Interim Director of Hematologic Malignancies Program
Interim Director of Blood & Bone Marrow Stem Cell Transplantation/Cellular Therapy Program
A051901 - A Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
CIBMTR/NMDP - Protocol for a Research Data Base for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries.
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors.
High Dose Cyclophosphamide, BCNU, Etoposide (CBV) or Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) and Autologous Hematopoietic Stem Cell Transplantation for Resistant and Relapsed Hodgkin's Disease and Non-Hodgkin's Lymphoma.
High Dose Cyclophosphamide, Thiotepa & Etoposide Followed by Autologous Hematopoietic Stem Cell Transplantation (Intermediate & High Grade).
Autologous Hematopoietic Stem Cell Transplantation After Melphalan with or without Total Body Irradiation for Multiple Myeloma.
Autologous Hematopoietic Stem Cell and/or Bone Marrow Transplantation after High Dose Chemotherapy (Carboplatinum, Etoposide) in Patients with Recurrent/Refractory Germ Cell Tumors.
DISEASES & CONDITIONS TREATED
All Cancers and Hematological Conditions
TREATMENTS / SERVICES
Oswego Hospital Health Services Center
140 West Sixth Street
Oswego, NY 13126
CLINICAL SECTION AFFILIATIONS
Hematology and Oncology
Upstate Cancer Center
CURRENT HOSPITAL PRIVILEGES
Upstate University Hospital